LeonardFeinerMDPhD

Ophthalmology • Union, NJ

Retinal Disease

Partner, NJRetina formerly known as Retina Associates of New Jersey

Join to view full profile

Dr. Feiner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Feiner's full profile

Already have an account?

Office
1000 Galloping Hill Rd
Ste 305
Union, NJ 07083
Phone+1 908-458-8333

Fax+1 908-458-8339

Summary

Dr. Leonard Feiner returned to his home state of New Jersey and joined NJ Retina in 2006. Dr. Feiner graduated magna cum laude from Princeton University with a degree in Mechanical and Aerospace Engineering. After deciding that medicine was his calling, he was awarded a grant from the National Institutes of Health to support his studies at the University of Pennsylvania School of Medicine, where he received his MD and a PhD in neuroscience.

Dr. Feiner joined the ophthalmology residency training program at the Scheie Eye Institute at the University of Pennsylvania, where he was the chief resident, followed by a two-year fellowship in vitreoretinal disease and surgery and ocular oncology at the Barnes Retina Institute, Washington University, St. Louis. Dr. Feiner has been the recipient of numerous honors and awards for excellence in ophthalmological research, receiving the Association of University Professors of Ophthalmology Resident Award, Ronald G. Michels Foundation Fellowship, and Heed Foundation Fellowship.

Dr. Feiner is on the medical staff of Clara Maass Medical Center and Hackensack University Medical Center. He is currently president of the New Jersey Retina Society.

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Surgical Retina and Vitreous, 2004 - 2006
University of Pennsylvania Health System/Scheie Eye InstituteResidency, Ophthalmology, 2001 - 2004
Presbyterian Medical Center of the University of Pennsylvania Health SystemInternship, Transitional Year, 2000 - 2001
Perelman School of Medicine at the University of PennsylvaniaClass of 2000
Princeton UniversityBSE, 1988 - 1992

Certifications & Licensure

NJ State Medical License 2006 - 2025
PA State Medical License 2001 - 2004
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Fellow Ronald G. Michels Foundation, 2005
Fellow Heed Foundation, 2004
Resident Award Association of University Professors of Ophthalmology, 2003
Chief Resident Scheie Eye Institute, 2003
Travel Fellow National Eye Institute, ARVO, 2002
Charles A. Oliver memorial prize for highest record of performance in ophthalmology 2000
George W. Householder prize for meritorious research 2000
Saul Winegrad award for outstanding Ph.D. dissertation 1999
John G. Clark prize for meritorious research 1998
Developmental biology training grant recipient NIH, 1997
Medical scientist training program grant recipient NIH, 1992
Ron Michels Fellow Ron Michels Foundation
Alpha Omega Alpha (AOA) Honor Society
Alpha Omega Alpha Honor Society AOA
Heed Fellow Heed
Fellow (FAAO) American Academy of Ophthalmology
President of New Jersey Retina Society NJ Retina Society
Join now to see all

Clinical Trials

Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema Start of enrollment: 2006 Jul 01
Completed
Phase 2
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implant Start of enrollment: 2002 May 01
Terminated
Phase 2, Phase 3
Efficacy of Fluocinolone Acetonide Intravitreal Implant in Diabetic Macular Edema Start of enrollment: 2001 Sep 01
Completed
Phase 2, Phase 3
Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial. Start of enrollment: 2008 Dec 01
Completed
Phase 3
Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial. Start of enrollment: 2008 Dec 01
Completed
Phase 3
Safety and Efficacy Study of Intravitreal Ocriplasmin in Subjects With AMD With Focal Vitreomacular Adhesion Start of enrollment: 2010 Jan 01
Completed
Phase 2
Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy Start of enrollment: 2009 Oct 01
Completed
Phase 2
Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies Start of enrollment: 2011 May 01
Completed
Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Start of enrollment: 2011 Apr 01
Completed
Phase 3
Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole Start of enrollment: 2011 Oct 01
Completed
Phase 3
Effect of Intravitreal Long Acting Dexamethasone Implant, Ozurdex in Patients With Diabetic Macular Edema Start of enrollment: 2011 Dec 01
Completed
Not Applicable
Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis Start of enrollment: 2012 Jun 01
Completed
Phase 1
Ocriplasmin Research to Better Inform Treatment (ORBIT) Start of enrollment: 2014 May 01
Completed
Join now to see all

Publications & Presentations

PubMed

5 citations
PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.
Calvin E. Mein, Pravin U. Dugel, Leonard Feiner, Kim Drenser, Daniel M. Miller
Retina. 2020-07-01
79 citations
Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial
Pravin U. Dugel, Michael J. Tolentino, Leonard Feiner, Petra Kozma, Annick Leroy
Ophthalmology. 2016-10-01
37 citations
One-year outcomes of eyes treated with a sutureless scleral fixation technique for intraocular lens placement or rescue.
John D. Wilgucki, H. Matthew Wheatley, Leonard Feiner, Mark V. Ferrone, Jonathan L. Prenner
Retina. 2015-05-01

Journal Articles

A Novel Approach for Posterior Chamber Intraocular Lens Placement or Rescue Via a Sutureless Scleral Fixation Technique
Prenner JL, Feiner L, Wheatley HM, Connors D, Retina, 2/1/2012
Incidence of Retinal Pigment Epithelial Tears After Intravitreal Ranibizumab Injection for Neovascular Age-Related Macular Regeneration
Cunningham ET, Feiner L, Chung C, Tuomi L, Ehrlich JL, Ophthalmology, 8/1/2011
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion Six-Month Primary End Point Results of a Phase III Study
Campochiaro PA, Heier J, Feiner L, Gray S, Saroj N, Rundle AC, Murahashi WY Rubio RG; BRAVO Study Group, Ophthalmology, 3/1/2010
Macular optical coherence tomography findings in progressive outer retinal necrosis
Almony A, Dhalla MS, Feiner L, Shah GK, Can J Ophthalmol, 12/1/2007
Analysis of kinesin-2 function in photoreceptor cells using synchronous Cre-loxP knockout of Kif3a with RHO-Cre
Jimeno D, Feiner L, Lillo C, Teofilo K, Goldstein LS, Pierce EA, Williams DS, Invest Ophthalmol Vis Sci, 11/1/2006
Retinal Vascular Diseases in Children
Feiner L and Prenner JL, Review of Ophthalmology, 4/1/2006
Vitreous and Aqueous Penetration of Orally Administered Moxifloxacin in Humans
Hariprasad, S, Blinder KJ, Feiner L, Chi J, Prince RA. Shah GK, Archives of Ophthalmology, 1/1/2006
Collaborative Initial Glaucoma Treatment Study: A summary of results to date
Feiner L and Seymour-Piltz, Current Opinions in Ophthalmology, 1/1/2003
Cavernous sinus fistulas
Feiner L, Bennett J, Volpe NJ, Curr Neurol Neurosci Rep, 1/1/2003
Targeted disruption of semaphorin 3C leads to persistent truncus arteriosus and aortic arch interruption
Feiner L. Webber AL. Brown CB. Lu MM. Jia L. Feinstein P. Mombaerts P. Epstein JA. Raper JA, Development, 1/1/2001
PlexinA2 and semaphorin signaling during cardiac neural crest development
Feiner L, Lu MM. Webber AL. Jia L. Raper JA. Epstein JA, Development, 1/1/2001
A high-resolution radiation hybrid map of the proximal portion of mouse chromosome 5
Tarantino LM. Feiner L. Alavizadeh A. Wiltshire T. Hurle B. Ornitz DM. Webber AL. Raper J. Lengeling A. Rowe LB. Bucan M, Genomics, 1/1/2000
A dominant negative receptor for specific secreted semaphorins is generated by deleting an extracellular domain from neuropilin-1
Renzi MJ. Feiner L. Koppel AM. Raper JA, Journal of Neuroscience, 1/1/1999
Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165
Miao HQ. Soker S. Feiner L. Alonso JL. Raper JA. Klagsbrun M, Journal of Cell Biology, 1/1/1999
Secreted chick semaphorins bind recombinant neuropilin with similar affinities but bind different subsets of neurons in situ
Feiner L. Koppel AM. Kobayashi H. Raper JA, Neuron, 1/1/1997
A 70 amino acid region within the semaphorin domain activates specific cellular response of semaphorin family members
Koppel AM. Feiner L. Kobayashi H. Raper JA, Neuron, 1/1/1997
Monoclonal antibody PHF-1 recognizes tau protein phosphorylated at serine residues 396 and 404
Otvos L Jr. Feiner L. Lang E. Szendrei GI. Goedert M. Lee VM, Journal of Neuroscience Research, 1/1/1994
Join now to see all